Low Carissa A, Bartel Christianna, Durica Krina, Donovan Heidi S, Thomas Roby, Fedor Jennifer
University of Pittsburgh, Pittsburgh, PA.
University of Pittsburgh Medical Center, Pittsburgh, PA.
JCO Clin Cancer Inform. 2025 Jul;9:e2500111. doi: 10.1200/CCI-25-00111. Epub 2025 Jul 11.
Consumer wearable devices provide new opportunities for measuring patterns of objective daily physical activity throughout cancer treatment. In addition to capturing step counts, these devices can also measure gait cadence and activity fragmentation, two metrics that may reflect functional capacity. The goal of the current study was to examine whether step count, gait cadence, and activity fragmentation predicted overall survival in patients with solid tumors.
We enrolled patients (N = 213) receiving outpatient chemotherapy for any solid tumor into an observational cohort study. Patients wore a consumer wearable device to measure continuous physical activity patterns for up to 90 days and were followed for a median of 2.53 years, during which 42% of the sample died. Univariable and multivariable Cox proportional hazards regression analyses were used to evaluate associations between wearable device physical function metrics and survival.
In univariable analyses, higher step count (hazard ratio (HR), 0.87; = .007), less activity fragmentation (HR, 1.03; < .001), and faster peak gait cadence (HR, 0.81; < .001) were significantly associated with lower mortality risk. Associations with activity fragmentation and gait cadence persisted after adjustment for age and cancer type and stage and after additional adjustment for clinician-rated performance status and patient-reported physical function.
Activity fragmentation and gait cadence metrics derived from consumer wearable devices were associated with overall survival in patients receiving chemotherapy for any solid tumor. These associations remained statistically significant after adjustment for covariates, including clinician-rated performance status and patient-reported physical function. These findings suggest that wearable devices may capture important prognostic information about physical function independent of what clinicians and patients perceive.
消费级可穿戴设备为在整个癌症治疗过程中测量客观日常身体活动模式提供了新机会。除了记录步数外,这些设备还可以测量步态节奏和活动碎片化程度,这两个指标可能反映功能能力。本研究的目的是检验步数、步态节奏和活动碎片化程度是否能预测实体瘤患者的总生存期。
我们将接受任何实体瘤门诊化疗的患者(N = 213)纳入一项观察性队列研究。患者佩戴消费级可穿戴设备,测量长达90天的持续身体活动模式,并随访中位时间为2.53年,在此期间42%的样本死亡。采用单变量和多变量Cox比例风险回归分析来评估可穿戴设备身体功能指标与生存之间的关联。
在单变量分析中,步数较多(风险比(HR),0.87;P = .007)、活动碎片化程度较低(HR,1.03;P < .001)以及峰值步态节奏较快(HR,0.81;P < .001)与较低的死亡风险显著相关。在调整年龄、癌症类型和分期后,以及在进一步调整临床医生评定的表现状态和患者报告的身体功能后,与活动碎片化程度和步态节奏的关联仍然存在。
来自消费级可穿戴设备的活动碎片化程度和步态节奏指标与接受任何实体瘤化疗患者的总生存期相关。在调整协变量(包括临床医生评定的表现状态和患者报告的身体功能)后,这些关联在统计学上仍然显著。这些发现表明,可穿戴设备可能捕捉到与临床医生和患者认知无关的有关身体功能的重要预后信息。